Next Article in Journal
Engineering Hepadnaviruses as Reporter-Expressing Vectors: Recent Progress and Future Perspectives
Previous Article in Journal
Cloning and Characterization of Sf9 Cell Lamin and the Lamin Conformational Changes during Autographa californica multiple nucleopolyhedrovirus Infection
Article Menu

Export Article

Open AccessCommunication
Viruses 2016, 8(5), 128; doi:10.3390/v8050128

Divergent Trends of Anti-JCPyV Serum Reactivity and Neutralizing Activity in Multiple Sclerosis (MS) Patients during Treatment with Natalizumab

1
Laboratorio di Microbiologia e Virologia, Università “Vita-Salute” San Raffaele, Milan 20132, Italy
2
Multiple Sclerosis Center, Spedali Civili of Brescia, Brescia 25123, Italy
3
Neurological Department, IRCCS Hospital San Raffaele, Milan 20132, Italy
4
Ospedale San Raffaele, Milan 20132, Italy
*
Author to whom correspondence should be addressed.
Academic Editor: Curt Hagedorn
Received: 9 February 2016 / Revised: 29 March 2016 / Accepted: 26 April 2016 / Published: 7 May 2016
(This article belongs to the Section Antivirals & Vaccines)
View Full-Text   |   Download PDF [625 KB, uploaded 7 May 2016]   |  

Abstract

The association between natalizumab and progressive multifocal leukoencephalopathy (PML) is established, but a reliable clinical risk stratification flow-chart is lacking. New risk factors are needed, such as the possible role of the anti-JC polyomavirus (JCPyV) neutralizing antibody. In this pilot study, we analyzed this parameter during natalizumab treatment. Sequential sera of 38 multiple sclerosis patients during their first year of natalizumab treatment were collected, and grouped according to the number of infusions. For 11 patients, samples were also available after 24 infusions (T24), when progressive multifocal leukoencephalopathy (PML) risk is higher. The reactivity against VP1, the main JCPyV surface protein, and the anti-JCPyV neutralizing activity were evaluated. During the first year, a lack of correlation between anti-JCPyV antibody response and its neutralizing activity was observed: a significant decrease in anti-JCPyV antibody response was observed (p = 0.0039), not paralleled by a similar trend in the total anti-JCPyV neutralizing activity (p = 0.2239). This lack of correlation was even more evident at T24 when, notwithstanding a significant increase in the anti-JCPyV response (p = 0.0097), a further decrease of the neutralizing activity was observed (p = 0.0062). This is the first study evidencing, prospectively, the lack of correlation between the anti-JCPyV antibody response and its neutralizing activity during natalizumab treatment. View Full-Text
Keywords: multiple sclerosis; natalizumab; progressive multifocal leukoencephalopathy; humoral response multiple sclerosis; natalizumab; progressive multifocal leukoencephalopathy; humoral response
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Diotti, R.A.; Capra, R.; Moiola, L.; Caputo, V.; De Rossi, N.; Sangalli, F.; Martinelli, V.; Burioni, R.; Clementi, M.; Mancini, N. Divergent Trends of Anti-JCPyV Serum Reactivity and Neutralizing Activity in Multiple Sclerosis (MS) Patients during Treatment with Natalizumab. Viruses 2016, 8, 128.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Viruses EISSN 1999-4915 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top